Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report.

Key Points

• To highlight the management of suspected Epstein-Barr Virus-associated hemophagocytic lymphohistiocytosis in a cholangiocarcinoma patient after targeted therapies.
• Presented a case study of a patient with cholangiocarcinoma and suspected EBV-associated HLH
• Sequential therapy included immune checkpoint inhibitors and BRAF/MEK inhibitors
• Emphasized the importance of a multidisciplinary approach for urgent diagnosis and management.
• Successful identification of HLH in the context of ICI therapy
• Prompt multidisciplinary management led to improved outcomes for the patient
• Highlighting the need for heightened awareness of HLH in patients receiving similar cancer therapies.

Abstract